Is scRNA-seq Enough? A Biological Question-Driven Guide to Single-Cell Multiome

Meta Intent: Help PIs and senior researchers who already use single-cell RNA sequencing determine, based on their specific biological hypothesis, whether upgrading to single-cell multiome (RNA + ATAC, RNA + protein, or higher-order combinations) is scientifically justified -without defaulting to the assumption that more modalities are always better.

Single-cell RNA sequencing (scRNA-seq) has transformed how we discover cell types, map developmental trajectories, and characterize disease heterogeneity. But as projects mature and biological questions deepen, many researchers face the same question: Should I keep scaling up scRNA-seq, or is it time to add another modality?

The answer is not "multiomics is more advanced." The answer depends entirely on what you need to see. Each modality layer -chromatin accessibility, protein abundance, DNA methylation -reveals a distinct facet of cellular biology that scRNA-seq alone cannot access. The decision to add them should be driven by your hypothesis, not by technological momentum.

This guide provides a practical framework for that decision. We cover what scRNA-seq can and cannot tell you, what biological information each multiome modality adds, four common decision scenarios, experimental design trade-offs when upgrading, and limitations to consider before adding complexity.

What scRNA-seq Does Well -and Where It Stops

scRNA-seq measures the polyadenylated transcriptome at single-cell resolution. When your biological question centers on gene expression -which genes are turned on, in which cells, and how those patterns change across conditions -scRNA-seq is a mature, well-supported, and cost-effective solution.

Questions scRNA-seq answers directly:

• Which cell types are present in my tissue sample, and what are their transcriptional signatures?
• Which genes are differentially expressed between conditions, and in which cell types?
• What developmental or transitional trajectories do cells follow?
• How does gene expression heterogeneity relate to disease state or treatment response?

These are transcriptional questions, and for these, scRNA-seq delivers high-quality answers. The technology benefits from years of protocol optimization (10x Genomics Chromium, Drop-seq, Smart-seq2), mature computational pipelines (Seurat, Scanpy, Monocle), and extensive community knowledge about normalization, batch correction, and clustering.

What scRNA-seq cannot see, however, is equally important. The transcriptome is not the entire cell. Several critical biological dimensions remain opaque to RNA measurement alone:

• Chromatin accessibility. Gene expression is regulated by chromatin state, but scRNA-seq captures only the final RNA product. The regulatory events that precede transcription -transcription factor binding, enhancer activation, nucleosome positioning -are invisible.
• Protein abundance. The correlation between mRNA and protein levels is modest (r ≈ 0.3-0.5), due to post-transcriptional regulation, differential translation rates, and protein turnover. A change in RNA does not guarantee a change in protein, and vice versa.
• Spatial context. Standard scRNA-seq requires tissue dissociation, which destroys spatial relationships. Neighbor-dependent signaling, tissue architecture, and microenvironment interactions are lost.
• Clonal architecture. Transcriptional similarity does not imply genetic relatedness. Without genome-level information, scRNA-seq cannot distinguish clonal populations within transcriptionally similar cell groups.

Recognizing these boundaries is not a weakness of scRNA-seq -it is simply the definition of what the transcriptome is. The question is whether your hypothesis crosses these boundaries. When the answer is that your question remains firmly transcriptional, a well-executed RNA-Seq experiment with adequate cell numbers and replicates continues to be the most efficient path to a clear result.

Figure 1: The Information Boundary of scRNA-seq

What Single-Cell Multiome Actually Adds -Three Biological Information Layers

Single-cell multiome encompasses several distinct modality pairings. Each pairing adds a specific type of biological information that RNA alone cannot provide. Understanding these differences is essential for choosing the right upgrade path.

Layer 1 -RNA + ATAC (Chromatin Accessibility)

The most widely adopted multiome pairing simultaneously profiles gene expression and chromatin accessibility from the same nucleus. Technologies include the 10x Genomics Chromium Single Cell Multiome ATAC + Gene Expression platform and emerging lower-cost alternatives such as Parallel-seq (Cell Reports Methods, 2025).

This pairing adds three biologically distinct capabilities:

• Feature linkage. By measuring ATAC-seq peaks and gene expression from the same nucleus, multiome data can link open chromatin regions to their target genes within individual cells. This reveals enhancer-promoter pairs, candidate cis-regulatory elements, and the chromatin landscape that shapes cell-type-specific expression.
• Chromatin potential. Chromatin accessibility at regulatory elements often changes before gene expression. This "chromatin potential" can predict cell fate decisions earlier than the transcriptome shifts -particularly valuable for developmental trajectory analysis.
• Transcription factor motif footprinting. Open chromatin regions contain sequence motifs for transcription factors. By analyzing which motifs are accessible in which cells, researchers can infer transcription factor activity at single-cell resolution, providing mechanistic insight into which regulators drive observed expression programs. For projects where chromatin accessibility alone is the primary question, standalone ATAC-Seq remains a proven option; the multiome upgrade adds value specifically when linking these regulatory events to gene expression output within the same cell.

Figure 2: RNA + ATAC Multiome Information Layers

Layer 2 -RNA + Protein (CITE-seq / Antibody-Oligo Methods)

CITE-seq (Cellular Indexing of Transcriptomes and Epitopes by Sequencing) and related methods (REAP-seq, ASAP-seq) use antibody-conjugated oligonucleotides to simultaneously measure cell-surface protein abundance alongside the transcriptome.

This pairing addresses the well-documented gap between RNA and protein levels. For many functional markers -particularly immune checkpoint proteins, cytokine receptors, and signaling molecules -transcript abundance is a poor proxy for surface protein expression. CITE-seq provides direct protein measurement without requiring a separate flow cytometry experiment.

CITE-seq is especially valuable for:

• Immune cell state annotation. Cell-surface protein markers define immune cell subsets with higher resolution than transcriptome data alone. Distinguishing naive from memory T cells, identifying regulatory T cells, or characterizing myeloid subpopulations is substantially more accurate when 100-200 surface protein markers are measured alongside the transcriptome.
• Antibody-accessible biomarker discovery. When the goal is to identify markers that can be translated to translational applications, measuring surface protein directly bridges the gap between discovery and application.
• Sample multiplexing. Antibody-oligo conjugates can also be used for sample hashing, allowing multiple samples to be pooled in a single scRNA-seq run, reducing batch effects and per-sample cost.

Figure 3: RNA + Protein Multiome (CITE-seq) Workflow

Layer 3 -Trimodal and Emerging Higher-Order Multiome

Emerging methods combine three or more modalities in the same cell. TEA-seq simultaneously profiles RNA, ATAC, and protein from the same cell. scNMT-seq adds DNA methylation to the transcriptome.

For most research questions, two modalities (RNA + ATAC or RNA + protein) provide the best balance of information gain and experimental feasibility. Trimodal approaches are currently best reserved for projects where mechanistic questions specifically require linking three molecular layers simultaneously.

When scRNA-seq Is Still the Right Answer

Before considering an upgrade, it is worth identifying the scenarios where scRNA-seq alone remains the optimal choice.

• Your question is purely transcriptional. If the core hypothesis involves differential gene expression, cell-type discovery, or transcriptional trajectory mapping -and no regulatory mechanism or protein-level validation is required -scRNA-seq is the proven, cost-effective solution.
• You prioritize cellular throughput. For the same budget, scRNA-seq delivers more cells than any multiome approach. If your experiment requires deep sampling of rare populations or broad cell-type discovery across many samples, scRNA-seq maximizes statistical power per dollar.
• Your samples are fresh or high-quality frozen tissue. Multiome protocols often require nuclei isolation rather than whole cells, which adds preparation steps and potential quality risks. If RNA quality is marginal, adding a second modality increases the probability of partial or complete data loss.
• Your bioinformatics pipeline is not ready for multi-modal analysis. Multiome data requires specialized analysis pipelines that integrate modalities. If your current analysis environment is optimized for scRNA-seq and the team lacks experience with multi-modal integration, the learning curve may outweigh the benefits.

Cost-Benefit Comparison: scRNA-seq vs Multiome

Figure 4: Cost-Benefit Comparison Table

When to Add ATAC (Chromatin Accessibility)

Adding chromatin accessibility to your single-cell workflow is scientifically justified when your hypothesis extends beyond "which genes are expressed" to "why and how they are regulated."

• Your hypothesis involves gene regulation. If the central question of your study is identifying which transcription factors drive a gene expression program, or which enhancers control cell-type-specific expression, multiome data provides the direct evidence. Feature linkage from joint RNA+ATAC measurements can connect open chromatin regions to their target genes.
• You need to identify enhancer-promoter pairs. Multiome feature linkage analysis correlates ATAC peak accessibility with nearby gene expression across cells. This enables genome-wide identification of candidate enhancer-promoter pairs operating in specific cell types -information critical for interpreting non-coding genetic variants.
• You are studying developmental trajectories. Chromatin accessibility at regulatory elements often shifts before transcription. This asynchrony means chromatin potential can predict cell fate earlier than transcriptome changes.
• Your disease involves epigenetic dysregulation. In cancer, the enhancer landscape is frequently rewired through mutations in non-coding regions, copy number alterations affecting regulatory elements, and changes in chromatin modifier expression. Multiome analysis captures both the regulatory rewiring and its transcriptional consequences in the same cell.
• You need better subtype resolution. Some cell populations that appear transcriptionally homogeneous have distinct chromatin landscapes. The ATAC modality often resolves subtypes that RNA alone groups together. For studies that additionally require genetic context -such as linking non-coding regulatory variants to chromatin changes -pairing multiome with Whole Exome Sequencing on the same samples can anchor regulatory findings to specific coding mutations.

Figure 5: When to Add ATAC -Decision Flowchart

When to Do RNA + Protein (CITE-seq)

Adding protein-level measurement is most valuable when transcript abundance is not a reliable proxy for protein function.

• Transcript-protein correlation is weak for your markers. The correlation between mRNA and protein is gene-specific. Cytokine receptors, chemokine receptors, and immune checkpoint molecules frequently show poor RNA-protein concordance. If your study focuses on such markers, CITE-seq provides direct protein quantification.
• Cell-surface proteins define your cell types. In immunology, cell-surface markers are the gold standard for defining cell subsets. CD4 and CD8 define T cell lineages, CD45RA and CCR7 distinguish naive from memory states, and CD25 and FOXP3 identify regulatory T cells.
• You need high-confidence cell annotation. Adding 100-200 protein markers to a scRNA-seq experiment dramatically improves cell-type annotation accuracy. For studies where annotation quality is mission-critical, the added protein dimension provides confidence that RNA-based annotation alone cannot match.
• You are multiplexing samples. Antibody-oligo hashing (Cell Hashing, MULTI-seq) uses lipid-tagged or antibody-conjugated oligonucleotides to label cells from different samples before pooling, reducing batch effects and per-sample cost while adding protein measurement as a bonus.

Figure 6: RNA + Protein Multiome Decision Guide

When to Consider Higher-Order Multiome

Trimodal assays (RNA + ATAC + protein) and combined epigenome-transcriptome approaches (scNMT-seq) serve specialized use cases:

• When your hypothesis requires linking all three layers -for example, asking whether a chromatin change leads to altered transcription, which in turn changes protein expression -and confirming all three in the same cell.
• When building a reference dataset that captures chromatin, RNA, and protein from the same cells as a community resource.
• When you have sufficient resources and technical expertise for the substantially higher complexity and cost.

For most laboratories, a trimodal approach should be considered only after confirming that the biological question cannot be answered with RNA + ATAC or RNA + protein alone.

A Practical Decision Framework -4 Questions

The following four-question framework translates the scenarios above into an actionable decision.

• Q1: Does my core hypothesis test purely transcriptional differences (cell types, differential expression, trajectory)? If yes: scRNA-seq is likely sufficient. Increasing cell number or biological replicates will often provide more value than adding a modality.
• Q2: Do I need to know why expression changes -which transcription factor, which enhancer, which regulatory element? If yes: add ATAC (chromatin accessibility). Multiome RNA + ATAC provides the feature linkage and TF footprinting data needed for mechanistic gene regulation analysis.
• Q3: Is protein-level confirmation or improved cell annotation critical for my conclusions? If yes: add protein (CITE-seq). This is particularly relevant for immunology studies, translational biomarker work, and any project where surface phenotype defines cell states.
• Q4: Does my project require simultaneous capture of regulatory, transcriptional, and protein-level data in the same cell? If yes: consider trimodal approaches, confirming that the added complexity is justified by a specific mechanistic question. A Multi-Omics Service that integrates experimental design support with modality-matched bioinformatics can help determine whether the added dimension justifies the cost and complexity for your specific project.

Figure 7: 4-Question Decision Tree

Experimental Design Considerations When Upgrading to Multiome

Moving from scRNA-seq to multiome requires adjustments across the experimental workflow.

• Sample requirements differ. RNA + ATAC multiome requires nuclei, not whole cells. The nuclei isolation protocol must preserve both accessible chromatin (for ATAC) and nuclear RNA (for gene expression). RNA + protein (CITE-seq) uses whole cells and is more similar to standard scRNA-seq sample preparation.
• Throughput is typically lower. The 10x Chromium Multiome platform captures 5,000-10,000 nuclei per channel -roughly half the throughput of standard scRNA-seq at equivalent cost. Emerging technologies like Parallel-seq claim higher throughput (200,000+ cells) but are not yet widely adopted.
• Sequencing depth requirements differ per library. Multiome experiments require sequencing both the ATAC library and the gene expression library from each partition. Typical recommendations are 25,000-50,000 read pairs per nucleus for ATAC and 20,000-50,000 reads per cell for the RNA library.
• Bioinformatics pipelines are modality-specific. Cell Ranger ARC is the standard processing pipeline for 10x Multiome data. Downstream integration tools include Seurat's multimodal framework, MOFA+, MultiVI, multiDGD, and scMODAL.
• Power analysis should account for both modalities. The scPower R package provides a framework for optimizing parameters across modalities. Pilot experiments with 2,000-5,000 nuclei per condition help estimate effect sizes before scaling up. Researchers studying histone modifications or transcription factor binding at higher resolution may also consider CUT&Tag Sequencing Service as a complementary epigenomic assay that requires fewer cells than conventional ChIP-seq, making it practical alongside multiome experiments with limited sample material.

Figure 8: Key Experimental Design Parameters Comparison

Limitations and Pitfalls of Multiome Approaches

Multiome methods are powerful, but they introduce limitations that are important to weigh honestly.

• Nuclear RNA bias. RNA + ATAC multiome captures only nuclear RNA, which represents a subset of the total transcriptome. Cytoplasmic transcripts -particularly those encoding secreted proteins, synaptic molecules in neurons, and long-lived mRNAs -are systematically underrepresented. Computational tools like GENESIS (Riva et al., 2025) address this gap but the limitation is inherent to the method.
• Compounded data sparsity. Each modality has its own drop-out pattern: ATAC detects only ~10-20% of accessible peaks per cell, and protein data has limited feature count. The union of sparsity patterns creates analysis challenges.
• Batch effects propagate across modalities. A batch effect in one modality can confound cross-modality integration. Balanced sample design, bridge samples, and batch-aware analysis are essential.
• Higher per-cell cost means fewer cells. For a fixed budget, multiome captures fewer cells than scRNA-seq, reducing power for rare population discovery.
• Tool maturity gap. Multiome analysis tools are actively evolving but less mature than scRNA-seq equivalents. Best practices are not yet as stable. For researchers who need epigenomic validation of multiome-predicted TF binding or histone modification patterns, ChIP-Seq provides an orthogonal, well-established method to confirm regulatory predictions generated from single-cell chromatin accessibility data.

Figure 9: Multiome Limitations Summary

How to Evaluate Whether Your Lab Should Upgrade

• Audit your recent scRNA-seq projects. What questions emerged that you could not answer with expression data alone? If the pattern is consistently "we wished we had chromatin data" or "protein-level confirmation would have changed our conclusions," that is a clear signal for upgrading.
• Run a pilot comparison. A small pilot experiment comparing scRNA-seq and multiome from the same sample -even 1,000-5,000 cells per modality -will reveal the information gain, technical challenges, and analysis requirements specific to your tissue and question.
• Consider the publication landscape. For mechanistic studies in high-impact journals, reviewer expectations increasingly include evidence at multiple omic levels. Demonstrating chromatin remodeling at the relevant enhancer alongside transcriptional change can substantially strengthen a manuscript.
• Evaluate service provider support. Does the provider offer integrated bioinformatics analysis that handles both modalities? The complexity of multi-modal data integration makes end-to-end service support a meaningful factor in project success.

Figure 10: Lab Upgrade Evaluation Framework

FAQ

Q: Can I integrate existing scRNA-seq data with new multiome data?
A: Yes, through computational integration methods. Tools like Seurat's bridge integration and scSHEFT can anchor multi-modal reference data to existing scRNA-seq datasets. However, matched multiome data from the same sample always provides higher power.

Q: Do I need to change my sample collection protocol for multiome?
A: For RNA + ATAC multiome, yes -you need nuclei, not whole cells. Flash-frozen tissue works but the nuclei isolation protocol must be optimized for your tissue type. For CITE-seq, standard scRNA-seq sample preparation is compatible.

Q: How many cells do I need for a useful multiome experiment?
A: A minimum of 2,000-5,000 nuclei per condition for RNA + ATAC multiome. For rare cell populations, more may be needed. The ATAC modality is sparser than RNA, so higher cell counts improve resolution.

Q: Is multiome data compatible with standard scRNA-seq analysis tools?
A: Partially. Standard normalization and clustering tools apply to the RNA component. However, multi-modal integration, peak calling, feature linkage, and TF footprinting require specialized tools (Cell Ranger ARC, Signac, MOFA+, MultiVI).

Q: Can I add ATAC to archived frozen samples?
A: Yes, with caveats. Frozen samples can be used for nuclei isolation if preserved properly. Freeze-thaw cycles degrade both chromatin integrity and RNA quality.

Q: How long does multiome data analysis take compared to scRNA-seq?
A: Expect 2-3× longer total analysis time. The ATAC component adds peak calling, quality filtering, feature linkage analysis, and integration steps.

Q: What is the main reason multiome experiments fail?
A: Poor nuclei quality is the most common failure point. If nuclei isolation damages the nuclear membrane, RNA leaks out and ATAC signal is lost. Optimizing the isolation protocol for each tissue type is the single most important step.

References:

1. Wu X, Yang X, Dai Y, et al. Single-cell sequencing to multi-omics: technologies and applications. Biomarker Research. 2024;12:110. DOI: 10.1186/s40364-024-00643-4
2. Treppner M, et al. The performance of deep generative models for learning joint embeddings of single-cell multi-omics data. Frontiers in Molecular Biosciences. 2022;9:962644. DOI: 10.3389/fmolb.2022.962644
3. Schuster V, et al. multiDGD: A versatile deep generative model for multi-omics data. Nature Communications. 2024;15:10031. DOI: 10.1038/s41467-024-53340-z
4. Wang G, Zhao J, Lin Y, et al. scMODAL: a general deep learning framework for comprehensive single-cell multi-omics data alignment with feature links. Nature Communications. 2025;16:4994. DOI: 10.1038/s41467-025-60333-z
5. Wan C, Ji Z. Integrating multiple single-cell multi-omics samples with Smmit. bioRxiv. 2025. DOI: 10.1101/2023.04.06.535857
6. Riva SG, et al. GENESIS: Generating scRNA-Seq data from Multiome Gene Expression. bioRxiv. 2025. DOI: 10.1101/2025.05.06.652399
7. Zhang S, Xiao Y, Mo X, et al. Simultaneous profiling of RNA isoforms and chromatin accessibility of single cells of human retinal organoids. Nature Communications. 2024;15:8022. DOI: 10.1038/s41467-024-52335-0

Related Services

This document is for Research Use Only. Not for use in diagnostic procedures.